Skip to main content
Evidence Snapshot

Coagulation factor VIII

CHEMBL3143 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T11:19:15Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3143
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Coagulation factor VIII as ChEMBL target CHEMBL3143, mapped to UniProt P00451. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Coagulation factor VIII
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3143
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P00451
Coagulation factor VIII
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Coagulation factor VIII matters

As of 2026-09-13

Coagulation factor VIII is reviewed as Coagulation factor VIII (UniProt P00451); Coagulation factor VIII shows approved-linked disease relevance led by hemophilia A. 5 more disease programs remain visible in the same review block.; 14 linked drugs keep this evidence frame grounded.; the current evidence base includes 0 approved drugs, 9 compounds, and 4 assays, with lead potency reaching pChEMBL 5.1.

Disease context
hemophilia A

Coagulation factor VIII shows approved-linked disease relevance led by hemophilia A. 5 more disease programs remain visible in the same review block. 14 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ANTIHEMOPHILIC FACTOR, PEGYLATED (MW 20000) HUMAN SEQUENCE RECOMBINANT, DAMOCTOCOG ALFA PEGOL, EFANESOCTOCOG ALFA.

Start review with hemophilia A because it currently carries approved-linked support. Linked drugs include ANTIHEMOPHILIC FACTOR, PEGYLATED (MW 20000) HUMAN SEQUENCE RECOMBINANT, DAMOCTOCOG ALFA PEGOL, EFANESOCTOCOG ALFA, EFMOROCTOCOG ALFA. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 14 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 0 approved drugs, 9 compounds, and 4 assays for this target. The dominant activity type is KI. CHEMBL1614804 is the current potency anchor at pChEMBL 5.1.

Use CHEMBL1614804 as the tractability anchor when discussing potency (pChEMBL 5.1).

Activity source · ChEMBL 36 via Core Engine
pChEMBL 5.1
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Coagulation factor VIII matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P00451, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why hemophilia A is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

9
Total Compounds
4
Total Assays
0
Approved Drugs
IC50: 2.0, KI: 3.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL1614804
 5.1 IC50 —
No preferred name
CHEMBL261865
 5.0 IC50 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T11:19:15Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3143